Coherus Oncology, Inc. (CHRS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$115.5M
Cash & Equivalents
$57.9M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$238M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-30 | Phase1 Readout | — |
Active Clinical Trials (9)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06457503 | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasophary... | PHASE4 | Recruiting | 100 |
| NCT07281716 | Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC | PHASE2 | Recruiting | 24 |
| NCT06940180 | Toripalimab With Chemotherapy for Sinus Cancer | PHASE2 | Recruiting | 20 |
| NCT07140679 | Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or ... | PHASE2 | Recruiting | 40 |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca... | PHASE2 | Recruiting | 75 |
| NCT06679985 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locall... | PHASE2 | Active Not Recruiting | 72 |
| NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants... | PHASE2 | Recruiting | 107 |
| NCT06657144 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced So... | PHASE1 | Recruiting | 154 |
| NCT05635643 | Study of CHS-114 in Participants With Advanced Solid Tumors | PHASE1 | Recruiting | 87 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.